KR100812406B1 - 혈관형성 억제 활성을 갖고 항응고 효과는 없는부분적으로 탈황산화된 글리코스아미노글리칸의 유도체 - Google Patents

혈관형성 억제 활성을 갖고 항응고 효과는 없는부분적으로 탈황산화된 글리코스아미노글리칸의 유도체 Download PDF

Info

Publication number
KR100812406B1
KR100812406B1 KR1020027009395A KR20027009395A KR100812406B1 KR 100812406 B1 KR100812406 B1 KR 100812406B1 KR 1020027009395 A KR1020027009395 A KR 1020027009395A KR 20027009395 A KR20027009395 A KR 20027009395A KR 100812406 B1 KR100812406 B1 KR 100812406B1
Authority
KR
South Korea
Prior art keywords
heparin
acid
modified
group
epoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027009395A
Other languages
English (en)
Korean (ko)
Other versions
KR20020080381A (ko
Inventor
카주베니토
토리지안지아코모
나기안나마리아
지안니니기우세페
피사노클라우디오
펜코세르지오
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20020080381A publication Critical patent/KR20020080381A/ko
Application granted granted Critical
Publication of KR100812406B1 publication Critical patent/KR100812406B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020027009395A 2000-01-25 2001-01-24 혈관형성 억제 활성을 갖고 항응고 효과는 없는부분적으로 탈황산화된 글리코스아미노글리칸의 유도체 Expired - Fee Related KR100812406B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000041A IT1316986B1 (it) 2000-01-25 2000-01-25 Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
ITRM2000A000041 2000-01-25

Publications (2)

Publication Number Publication Date
KR20020080381A KR20020080381A (ko) 2002-10-23
KR100812406B1 true KR100812406B1 (ko) 2008-03-11

Family

ID=11454382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009395A Expired - Fee Related KR100812406B1 (ko) 2000-01-25 2001-01-24 혈관형성 억제 활성을 갖고 항응고 효과는 없는부분적으로 탈황산화된 글리코스아미노글리칸의 유도체

Country Status (21)

Country Link
US (4) US20030013682A1 (https=)
EP (1) EP1268558B1 (https=)
JP (1) JP5371167B2 (https=)
KR (1) KR100812406B1 (https=)
CN (1) CN100540570C (https=)
AT (1) ATE348115T1 (https=)
AU (1) AU782632B2 (https=)
BR (1) BR0107696A (https=)
CA (1) CA2397964C (https=)
CY (1) CY1108001T1 (https=)
CZ (1) CZ303030B6 (https=)
DE (1) DE60125154T2 (https=)
DK (1) DK1268558T3 (https=)
ES (1) ES2277911T3 (https=)
HU (1) HU229509B1 (https=)
IT (1) IT1316986B1 (https=)
MX (1) MXPA02007195A (https=)
PL (1) PL209479B1 (https=)
PT (1) PT1268558E (https=)
SK (1) SK287566B6 (https=)
WO (1) WO2001055221A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
CZ307433B6 (cs) * 2001-09-12 2018-08-22 Leadiant Biosciences Sa Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
AU2008202261B2 (en) * 2001-09-12 2011-07-28 Leadiant Biosciences S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
AU2008318343B2 (en) * 2007-11-02 2013-07-18 Dilafor Ab Non-anticoagulant polysaccharide compositions
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
US8431826B2 (en) 2010-05-14 2013-04-30 James Robert Howard Capacitive power and ground plane structure utilizing fractal elements for the reduction of radiated emissions
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2617764C2 (ru) 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
MX363923B (es) 2011-12-28 2019-04-08 Galectin Therapeutics Inc Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
CA2875979C (en) 2012-06-06 2021-01-26 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9507912B2 (en) 2012-08-31 2016-11-29 Nuvectra Corporation Method and system of simulating a pulse generator on a clinician programmer
AU2013315019B2 (en) 2012-09-17 2017-06-01 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
JP6132302B2 (ja) * 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
ITLO20130005A1 (it) * 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
CN103724458B (zh) * 2014-01-17 2016-03-30 福州大学 含n-非取代葡萄糖胺肝素六糖的制备及其纯化
PL3265075T3 (pl) 2015-03-06 2020-10-05 Leadiant Biosciences S.P.A. Terapia skojarzona szpiczaka mnogiego obejmująca roneparstat
JP2016014148A (ja) * 2015-09-10 2016-01-28 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
CN107177015A (zh) * 2016-03-11 2017-09-19 梁颖 一种重乙酰化肝素修饰物及其制备方法和应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107200A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US11225531B2 (en) 2018-02-02 2022-01-18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Glycosaminoglycan derivative and preparation method therefor and use thereof
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027976A1 (en) 1997-11-28 1999-06-10 Baxter Biotech Technology S.A.R.L. Non thrombogenic polymers with compatibility with organic fluids and tissues

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IL79255A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH05157344A (ja) * 1991-12-09 1993-06-22 Mitsubishi Heavy Ind Ltd 空気調和機の吹出口
JPH0512822A (ja) 1991-12-16 1993-01-22 Seiko Epson Corp カートリツジ
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
IT1264709B1 (it) 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
AU2435795A (en) * 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
MY117098A (en) * 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
IT1296998B1 (it) * 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027976A1 (en) 1997-11-28 1999-06-10 Baxter Biotech Technology S.A.R.L. Non thrombogenic polymers with compatibility with organic fluids and tissues

Also Published As

Publication number Publication date
SK287566B6 (sk) 2011-02-04
JP5371167B2 (ja) 2013-12-18
US20050222084A1 (en) 2005-10-06
HUP0204196A2 (hu) 2003-03-28
EP1268558B1 (en) 2006-12-13
WO2001055221A1 (en) 2001-08-02
HUP0204196A3 (en) 2003-05-28
AU782632B2 (en) 2005-08-18
CA2397964A1 (en) 2001-08-02
ES2277911T3 (es) 2007-08-01
US20050107331A1 (en) 2005-05-19
AU3406401A (en) 2001-08-07
JP2003523460A (ja) 2003-08-05
IT1316986B1 (it) 2003-05-26
CZ20022308A3 (cs) 2003-01-15
US8222231B2 (en) 2012-07-17
SK10672002A3 (sk) 2002-12-03
ITRM20000041A1 (it) 2001-07-25
CN100540570C (zh) 2009-09-16
HU229509B1 (en) 2014-01-28
PT1268558E (pt) 2007-02-28
DE60125154D1 (de) 2007-01-25
ITRM20000041A0 (it) 2000-01-25
DE60125154T2 (de) 2007-10-25
MXPA02007195A (es) 2003-01-28
US7790700B2 (en) 2010-09-07
CZ303030B6 (cs) 2012-03-07
EP1268558A1 (en) 2003-01-02
ATE348115T1 (de) 2007-01-15
DK1268558T3 (da) 2007-04-10
BR0107696A (pt) 2002-10-15
HK1051867A1 (zh) 2003-08-22
CN1396930A (zh) 2003-02-12
CY1108001T1 (el) 2013-09-04
PL209479B1 (pl) 2011-09-30
KR20020080381A (ko) 2002-10-23
US20100298263A1 (en) 2010-11-25
PL357209A1 (en) 2004-07-26
CA2397964C (en) 2010-10-12
US20030013682A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
KR100812406B1 (ko) 혈관형성 억제 활성을 갖고 항응고 효과는 없는부분적으로 탈황산화된 글리코스아미노글리칸의 유도체
JP5816342B2 (ja) 非抗凝固性多糖組成物
Norrby Low‐molecular‐weight heparins and angiogenesis
EP1427427B1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
HUT59828A (en) Process for producing oligosaccharid-containing inhibitors of endothelial celle-multiplication and inhibitors of angiogenezis
US20110200673A1 (en) Oxidized heparin fractions and their use in inhibiting angiogenesis
JPH0273801A (ja) 選択的にｏ―アシル化されたグリコサミノグリカン
Mardhekar et al. Sulfation of Heparan and Chondroitin Sulfate Ligands Enables Cell‐Specific Homing of Nanoprobes
AU2010236222B2 (en) Methods of assessing activity of a polysaccharide composition
WO2002083155A1 (en) Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis
US20020013264A1 (en) Neoglycan anticancer agents and uses thereof
HK1051867B (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
AU2008202261A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080407

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1008124060000

Gazette reference publication date: 20080311

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130225

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140224

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20150225

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160305

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160305